BamSEC and AlphaSense Join Forces
Learn More

ARYx Therapeutics, Inc.

Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.6
from 8-K 26 pages Intellectual Property Security Agreement
12/34/56
EX-10.4
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 16 pages Security Agreement
12/34/56
EX-10.1
from 8-K 22 pages ARYx Therapeutics, Inc. Secured Note and Warrant Purchase Agreement
12/34/56
EX-10.1
from 8-K 10 pages June 2, 2010 1. Resignation. You Hereby Resign From All Positions That You Hold With the Company, Including Your Position on the Company’s Board of Directors, and the Company Hereby Accepts All Such Resignations, Effective June 15, 2010 (The “Separation Date”)
12/34/56
EX-10.1
from 8-K 36 pages At Market Issuance Sales Agreement
12/34/56
EX-10.32
from 8-K 93 pages Common Stock Purchase Agreement Dated as of October 6, 2009 by and Between ARYx Therapeutics, Inc. and Commerce Court Small Cap Value Fund, Ltd
12/34/56
EX-10.31
from 8-K 22 pages ARYx Therapeutics, Inc. Executive Severance Benefit Plan
12/34/56
EX-10.16
from 10-Q 2 pages ARYx Therapeutics, Inc. Non-Employee Director Compensation
12/34/56
EX-10.29
from 10-K 5 pages Amendment No. 1 to Employment Agreement
12/34/56
EX-10.28
from 10-K 4 pages Amendment No. 1 to Employment Agreement
12/34/56
EX-10.27
from 10-K 5 pages Amendment No. 1 to Employment Agreement
12/34/56
EX-10.26
from 10-K 4 pages Amendment No. 1 to Employment Agreement
12/34/56
EX-10.25
from 10-K 5 pages Amendment No. 1 to Employment Agreement
12/34/56
EX-10.20
from 8-K ~5 pages Compensation Information for Named Executive Officers
12/34/56
EX-10.24
from 8-K 61 pages Securities Purchase Agreement
12/34/56
EX-10.22
from 10-Q 3 pages Amendment to License, Development, and Commercialization Agreement
12/34/56
EX-10.20
from 8-K/A ~5 pages Compensation Information for Named Executive Officers
12/34/56
EX-10.20
from 8-K ~5 pages Compensation Information for Named Executive Officers
12/34/56
EX-10.17
from S-1/A 103 pages Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted and Filed Separately With the Securities and Exchange Commission Pursuant to Rule 406 of the Securities Act of 1933, as Amended
12/34/56